Zai Lab Limited (NASDAQ:ZLAB) CEO Sells $122,587.24 in Stock

Zai Lab Limited (NASDAQ:ZLAB) CEO Ying Du sold 7,013 shares of the company’s stock in a transaction that occurred on Monday, July 1st. The shares were sold at an average price of $17.48, for a total value of $122,587.24. Following the completion of the sale, the chief executive officer now owns 1,081,910 shares in the company, valued at approximately $18,911,786.80. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website.

Ying Du also recently made the following trade(s):

• On Wednesday, June 26th, Ying Du sold 23,939 shares of Zai Lab stock. The stock was sold at an average price of $17.90, for a total value of $428,508.10.

Zai Lab Stock Performance

Shares of NASDAQ ZLAB traded up $0.08 during trading hours on Tuesday, reaching $17.37. 297,748 shares of the stock were exchanged, compared to its average volume of 633,705. The firm has a market capitalization of $1.72 billion, a price-to-earnings ratio of -4.97 and a beta of 1.06. The stock’s fifty day simple moving average is $18.41 and its 200 day simple moving average is $19.98. Zai Lab Limited has a 52 week low of $13.48 and a 52 week high of $32.60.

Zai Lab (NASDAQ:ZLAB) last posted its quarterly earnings data on Wednesday, May 8th. The company reported ($0.55) earnings per share for the quarter, topping the consensus estimate of ($0.93) by $0.38. Zai Lab had a negative return on equity of 40.21% and a negative net margin of 116.45%. The firm had revenue of $87.15 million for the quarter, compared to analysts’ expectations of $77.07 million. During the same quarter last year, the business earned ($0.51) EPS. Research analysts predict that Zai Lab Limited will post -2.78 EPS for the current fiscal year.

Institutional Investors Weigh In On Zai Lab

Institutional investors have recently made changes to their positions in the stock. BNP Paribas Financial Markets raised its position in shares of Zai Lab by 51.2% during the first quarter. BNP Paribas Financial Markets now owns 2,671 shares of the company’s stock worth $43,000 after acquiring an additional 904 shares during the last quarter. Headlands Technologies LLC acquired a new position in shares of Zai Lab in the 1st quarter worth approximately $64,000. Tower Research Capital LLC TRC increased its position in shares of Zai Lab by 1,923.8% during the fourth quarter. Tower Research Capital LLC TRC now owns 2,550 shares of the company’s stock worth $70,000 after buying an additional 2,424 shares during the period. Sectoral Asset Management Inc. raised its position in shares of Zai Lab by 33.3% in the 4th quarter. Sectoral Asset Management Inc. now owns 4,000 shares of the company’s stock worth $109,000 after acquiring an additional 1,000 shares in the last quarter. Finally, SG Americas Securities LLC acquired a new position in shares of Zai Lab in the 4th quarter valued at about $116,000. 41.65% of the stock is currently owned by institutional investors.

Analyst Upgrades and Downgrades

Separately, Cantor Fitzgerald reiterated an “overweight” rating on shares of Zai Lab in a report on Monday. Five analysts have rated the stock with a buy rating, Based on data from MarketBeat, Zai Lab presently has a consensus rating of “Buy” and an average target price of $64.57.

Zai Lab Company Profile

Zai Lab Limited develops and commercializes therapies to treat oncology, autoimmune disorders, infectious diseases, and neuroscience. Its commercial products include Zejula, an orally administered poly polymerase 1/2 inhibitor; Optune, a cancer therapy that uses electric fields tuned to specific frequencies to kill tumor cells; NUZYRA for acute bacterial skin and skin structure infections, and community acquired bacterial pneumonia; Qinlock to treat gastrointestinal stromal tumors, and VYVGART, a human IgG1 antibody fragment for myesthenia gravis.